Immutep Limited (IMMP) News
Filter IMMP News Items
IMMP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMMP News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IMMP News From Around the Web
Below are the latest news stories about IMMUTEP LTD that investors may wish to consider to help them evaluate IMMP as an investment opportunity.
Patient Enrolment Completed for INSIGHT-003Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patientsData updates from INSIGHT-003 are expected in 2025 and beyond SYDNEY, AUSTRALIA, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today an |
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first half of CY2025IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan |
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IIFindings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 small molecule programData also supports eftilagimod alfa’s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Compan |
Immutep announces results from Cohort B of TACTI-003 trialImmutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA in first line recurrent/metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression. Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients whose tumours express PD-L1 below 1 and who typically do not respond well to anti-PD-1 therapy alone shows: Positively, |
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controlsComplete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectivelyTreatment continues to be well tolerated SYDNEY, AUS |
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerMedia Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC). “The receipt of regulatory approval from the Australian Therapeutic Goods Administrati |
Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 millionPrima raised $23 million in new Series A backing earlier this year, a few months before Donald Trump’s election victory. |
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerMedia Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controlsSafety continues to be favourable with no new |
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual MeetingMedia Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcomaOver three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage bi |
Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years agoIf you love investing in stocks you're bound to buy some losers. But long term Immutep Limited ( ASX:IMM ) shareholders... |